MAP2K7 and melanoma: STK19 kinase was a potential therapeutic target for NRAS-mutant melanomas; 5 and 20 μmol/L chelidonine inhibited STK19, and reduced the phosphorylation of NRAS S89, MEK, ERK1/2, and AKT in all four NRAS-mutant melanoma cell lines [36].